Breaks Categories: News

WednesdayJul 13, 2022 2:57 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast Spotlighting Two-Time Olympic Gold Medalist Abby Wambach

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, is featured in the latest episode of InvestorBrandNetwork’s Stock2Me podcast. Hosted by Stuart Smith, the podcast talks with soccer play Abby Wambach, an Olympic gold medalist and member of ODYY’s sports advisory board. During the interview, Wambach discusses her soccer career and why she was drawn to Odyssey, a medical technology company that is developing a drug/device combination intended to treat concussion. Wambach and other members of the sports advisory board support the company’s efforts to enhance public awareness of traumatic brain…

Continue Reading

WednesdayJul 13, 2022 2:31 pm

BioMedNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Lucid Psycheceuticals Files for Patent on Novel Formulations of Palmitoylethanolamide

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that is wholly owned subsidiary, Lucid Psycheceuticals Inc., filed a provisional patent application on novel formulations of palmitoylethanolamide (“PEA”). According to the update, the new patent application is based on the results of completed preclinical animal toxicology studies and phase 1 clinical trial using FSD201 (ultramicronized PEA), sponsored by FSD Pharma. The company is diligently pursuing the clinical development of FSD201 for various indications. FSD Pharma recently announced the submission of an Investigational New Drug…

Continue Reading

TuesdayJul 12, 2022 4:45 pm

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Announces Positive Results of New Study

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, today announced that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method. “The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic agents. We suggest that this drug delivery approach would not only enhance efficacy but also reduce systemic toxicity,” said Eric Weisblum, CEO of Silo Pharma. “In our previous work, ART-1-Cy7-liposomes injected i.v. demonstrated homing to arthritic joints and four hours was an optimal time point…

Continue Reading

TuesdayJul 12, 2022 3:23 pm

BioMedNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment

Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced commencement of enrollment in a phase 1/2a clinical trial of CYB003. Being developed by Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” CYB003 is the first novel psilocybin analog to be evaluated in phase 1/2a development for the treatment of major depressive disorder (“MDD”). “Clinilabs is honored to be working with Cybin, an innovator in the development of novel psychedelic therapeutics, to conduct its first-in-human clinical trial of CYB003,” said…

Continue Reading

TuesdayJul 12, 2022 3:08 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Single Ascending Dosing for Intranasal Concussion Drug

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in its Phase I Single Ascending Dosing (“SAD”) clinical trial. According to the update, Odyssey’s trial involves administering PRV-002, the company’s novel drug to treat concussion, to healthy human subjects. Concussions represent an “unmet” medical need and affect millions worldwide, while a single concussion can significantly increase the risk of Alzheimer’s and other neuropsychiatric disorders. “After reviewing the data from Cohort III and completing the SAD analysis, I have strong confidence that PRV-002 will…

Continue Reading

MondayJul 11, 2022 11:44 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a phase 1 N,N-dimethyltryptamine (“DMT”) study from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1). The DMT study, which is the largest to date, is expected to accelerate the clinical development path of Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, CYB004, by approximately nine months. “With the closing of this transaction, we are well on our way to advancing CYB004 through phase 1…

Continue Reading

FridayJul 08, 2022 10:58 am

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves One Step Closer to In-Human Trials with Completion of Preclinical Toxicity Study

Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, has successfully completed a toxicology study evaluating Adimune(TM), its proprietary therapeutic program. The study indicates the safety profile of ADI(TM)-100, ADTX’s immunotherapeutic technology drug, which is designed to treat the rejection of transplanted organs, skin allografting, autoimmune diseases and allergies. Calling the study results “promising,” the company noted that those results will provide vital supporting evidence when Aditxt moves forward with an investigational new drug (“IND”) application with the regulatory agencies. According to the announcement, ADI-100 is made of two DNA…

Continue Reading

WednesdayJun 29, 2022 11:56 am

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Completes Safety Evaluation of Cohort II for Novel Drug to Treat Concussion

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from cohort II of its phase I clinical trial. According to the update, the trial involves administering PRV-002, Odyssey’s novel drug to treat concussion, to healthy human subjects. Cohort II data indicates that the drug was safe and well-tolerated. “PRV-002 continues to be well-tolerated as we increase the intranasal dose levels,” said Michael Redmond, CEO of Odyssey Health. “We look forward to completing phase I clinical trials and moving into a phase II/III to determine the efficacy…

Continue Reading

TuesdayJun 28, 2022 12:46 pm

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Adelia Announce Achievement of Milestone

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), and its wholly controlled subsidiary Adelia Therapeutics Inc., have announced the achievement of a key milestone. The milestone is identified as Y2, Q3 in the contribution agreement created between Adelia and Cybin when the company acquired Adelia. Reaching the milestone means that an estimated 37,366.2 class B common shares in Cybin will be issued to Adelia shareholders; the issuance of the shares represents the approximately $217,465 that Cybin agreed to pay if the key milestone was achieved. Adelia…

Continue Reading

MondayJun 27, 2022 2:10 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Report of Annual General Meeting of Shareholders

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life-sciences holding company dedicated to building a portfolio of assets and biotech solutions, is reporting on its annual general meeting of shareholders; the meeting was held online on June 23, 2022. During the meeting, seven nominees were elected as directors of the company. The new directors are Anthony Durkacz, Zeeshan Saeed, Donal Carroll, Adnan Bashir, Fernando Cugliari, Nitin Kaushal and Lawrence Latowsky; the directors will serve until the next annual meeting of shareholders or until successors are elected or appointed. During the meeting, shareholders also reappointed MNP LLP as the company…

Continue Reading